Aptevo Therapeutics Inc (APVO) — Cash Flow-to-Debt Ratio
Aptevo Therapeutics Inc (APVO) has a Cash Flow-to-Debt Ratio of -0.96x as of March 2026, meaning its operating cash flow of $-7.96 Million could theoretically repay -1% of its total liabilities ($8.29 Million) in one year. Check APVO total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aptevo Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Aptevo Therapeutics Inc across 12 annual periods. Also explore APVO asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Aptevo Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Aptevo Therapeutics Inc. For market capitalisation and broader financial context, see APVO company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-25.59 Million | $9.81 Million | ▼ -18.8% |
| 2024 | -2.19x | $-23.79 Million | $10.84 Million | ▼ -136.2% |
| 2023 | -0.93x | $-11.73 Million | $12.62 Million | ▲ +28.2% |
| 2022 | -1.29x | $-21.02 Million | $16.24 Million | ▼ -230.7% |
| 2021 | -0.39x | $-21.68 Million | $55.38 Million | ▲ +50.7% |
| 2020 | -0.79x | $-29.32 Million | $36.95 Million | ▲ +22.2% |
| 2019 | -1.02x | $-42.38 Million | $41.57 Million | ▲ +26.5% |
| 2018 | -1.39x | $-51.42 Million | $37.09 Million | ▼ -16.6% |
| 2017 | -1.19x | $-41.57 Million | $34.97 Million | ▼ -33.2% |
| 2016 | -0.89x | $-36.86 Million | $41.29 Million | ▲ +56.4% |
| 2015 | -2.05x | $-48.76 Million | $23.84 Million | ▼ -10.4% |
| 2014 | -1.85x | $-47.01 Million | $25.36 Million | — |